Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Portage Biotech Inc. (NASDAQ: PRTG) announced participation in Citi's 2023 Virtual Oncology Leadership Summit scheduled for February 22, 2023, at 9:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Portage Biotech Inc. (NASDAQ: PRTG) announced participation in Citi's 2023 Virtual Oncology Leadership Summit scheduled for February 22, 2023, at 9:00 AM ET. The management team will engage in a fireside chat, which will be accessible via a webcast here. A replay will be available approximately 12 hours post-event and will be hosted on the investor section of the Portage Biotech website for one year. Portage is a clinical-stage immuno-oncology company focusing on multi-targeted cancer therapies, including first-in-class invariant natural killer T cell small molecule engagers and adenosine antagonists.
Details
News Market Reaction – PRTG
The recorded move for PRTG in the trading session of this news was -0.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023. Event details are below:
Citi's 2023 Virtual Oncology Leadership Summit
| Date / Time: | Wednesday, February 22, 2023 at 9:00am ET |
| Webcast: | https://kvgo.com/citi/portage-biotech-inc-feb-2023 |
A replay will be available about 12 hours after the conclusion of the live fireside chat, and will be posted on the investors section of the Portage Biotech website one year following the event.
About Portage Biotech Inc.
Portage is clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
Chuck Padala
chuck@lifesciadvisors.com
Media Relations
Gwendolyn Schanker
gschanker@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.